HR-18034

N/A

Report date: 2023/03/07 20:00:45
NME

Base Information

Drug NameHR-18034
Drug Alias NameHR-18034HR18034
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channels blockers
TargetsSodium channels
Therapy Area/IndicationsPainPain, PostoperativeOsteoarthritis, Knee +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Xinyue Pharmaceutical Co LtdShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsPain, PostoperativeOsteoarthritis, KneeAnesthesia
Inactive IndicationsPain

Other Information

ATC CodeN/A
Related LinksN/A